Symbio Holdings Limited
Symbio Holdings Limited Fundamental Analysis
Symbio Holdings Limited (SYM.AX) shows weak financial fundamentals with a PE ratio of 126.30, profit margin of 0.84%, and ROE of 1.08%. The company generates $0.2B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 38.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SYM.AX's fundamental strength across five key dimensions:
Efficiency Score
WeakSYM.AX struggles to generate sufficient returns from assets.
Valuation Score
ModerateSYM.AX shows balanced valuation metrics.
Growth Score
ModerateSYM.AX shows steady but slowing expansion.
Financial Health Score
ExcellentSYM.AX maintains a strong and stable balance sheet.
Profitability Score
ModerateSYM.AX maintains healthy but balanced margins.
Key Financial Metrics
Is SYM.AX Expensive or Cheap?
P/E Ratio
SYM.AX trades at 126.30 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, SYM.AX's PEG of 1.26 indicates fair valuation.
Price to Book
The market values Symbio Holdings Limited at 1.36 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 11.42 times EBITDA. This signals the market has high growth expectations.
How Well Does SYM.AX Make Money?
Net Profit Margin
For every $100 in sales, Symbio Holdings Limited keeps $0.84 as profit after all expenses.
Operating Margin
Core operations generate 1.92 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.08 in profit for every $100 of shareholder equity.
ROA
Symbio Holdings Limited generates $0.78 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Symbio Holdings Limited produces operating cash flow of $28.40M, showing steady but balanced cash generation.
Free Cash Flow
Symbio Holdings Limited produces free cash flow of $6.63M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.08 in free cash annually.
FCF Yield
SYM.AX converts 2.89% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
126.30
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.26
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.36
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.07
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.09
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.95
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.01
vs 25 benchmark
ROA
Return on assets percentage
0.008
vs 25 benchmark
ROCE
Return on capital employed
0.02
vs 25 benchmark
How SYM.AX Stacks Against Its Sector Peers
| Metric | SYM.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 126.30 | 33.61 | Worse (Expensive) |
| ROE | 1.08% | 1020.00% | Weak |
| Net Margin | 0.84% | -56528.00% (disorted) | Weak |
| Debt/Equity | 0.09 | 0.45 | Strong (Low Leverage) |
| Current Ratio | 1.95 | 5.65 | Neutral |
| ROA | 0.78% | -291484.00% (disorted) | Weak |
SYM.AX outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Symbio Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Growth, Innovation, High Beta
EPS CAGR
N/A
Industry Style: Growth, Innovation, High Beta
FCF CAGR
N/A
Industry Style: Growth, Innovation, High Beta